**Helicobacter pylori** promotes gastric epithelial cell survival through the PLK1/PI3K/Akt pathway

Wenting Xu
Ying Huang
Zhen Yang†
Yi Hu
Xu Shu
Chuan Xie
Cong He
Yin Zhu
Nonghua Lu

Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China

†Dr Zhen Yang passed away on November 14, 2016

**Purpose:** *Helicobacter pylori* (*H. pylori*) infection plays a critical role in the process of gastric carcinogenesis. However, the complicated pathogenic mechanism is still unclear. Polo-like kinase 1 (PLK1) is involved in the development of multiple human malignancies, including gastric cancer. Therefore, this study aimed to elucidate the role of PLK1 in *H. pylori*-induced gastric carcinogenesis and the underlying signaling mechanism.

**Materials and methods:** We detected the expression of PLK1 in 166 patients in different stages of gastric carcinogenesis as well as the established Mongolian gerbil model with *H. pylori* infection by immunohistochemistry. Cell Counting Kit-8 was used to estimate the survival of gastric cancer cells.

**Results:** We found that PLK1 expression in gastric cancer tissues was significantly higher than that of paired adjacent mucosa. PLK1 expression was increased in intestinal metaplasia, dysplasia, and gastric cancer tissues compared to chronic non-atrophic gastritis tissues. Notably, PLK1 expression was much lower in *H. pylori*-negative tissues than in *H. pylori*-positive tissues at intestinal metaplasia stage. In addition, *H. pylori* infection increased PLK1 expression in the gastric epithelial cells of the Mongolian gerbil model, which was positively related to the duration of *H. pylori* infection. Inhibition of PLK1 significantly reduced *H. pylori*-induced cell proliferation. Furthermore, incubation of MKN-28 cells with *H. pylori* resulted in a significant increase in PLK1, p-PTEN, and the downstream PI3K/Akt pathway, and pretreatment with a PLK1 inhibitor reversed these molecular changes.

**Conclusion:** PLK1 is involved in *H. pylori*-induced gastric carcinogenesis at the early stage by activating the PI3K/Akt signaling pathway. These results may contribute to the development of new control strategies for *H. pylori* infection-related gastric cancer.

**Keywords:** gastric carcinogenesis, *Helicobacter pylori*, PLK1, PI3K/Akt pathway, cell survival

**Introduction**

Gastric cancer is one of the most common cancers worldwide and the third and fifth leading cause of cancer-related deaths among females and males, respectively. Despite the decrease in incidence and mortality, gastric cancer is still one of the heaviest health burdens worldwide. To date, surgical resection remains the preferred curative method to improve survival of gastric cancer patients. However, for patients who have reached the terminal stage or are not accepted for surgical treatment, chemotherapy is an alternative, but it has some limitations due to its serious side effects. Therefore, it is necessary to elucidate the mechanism underlying gastric cancer development and progression, which will help to develop novel and effective strategies for gastric cancer treatment.

Polo-like kinase 1 (PLK1) is a serine/threonine kinase that participates in the regulation of various processes, including mitosis, cytokinesis, and the DNA damage
response. A number of studies have shown that PLK1 is highly expressed in multiple digestive tumors, such as esophageal cancer, gastric cancer, colorectal cancer, liver cancer, cholangiocarcinoma, and pancreatic cancer. Additionally, the high expression of PLK1 in gastric cancer is positively related to tumor stage, metastasis, invasion, and poor prognosis.

_Helicobacter pylori_ is a common bacterium with a high infection rate, which shows severe pathogenicity. With its unique virulence factors, it can adapt to the highly acidic microenvironment in the stomach cavity, colonize in the host body for a long period of time, and then induce a series of related diseases. Epidemiology confirms that gastritis, peptic ulcer, non-cardia gastric cancer, and low-grade B-cell MALT lymphoma are all associated with _H. pylori_ infection. As early as 1994, the International Agency for Research on Cancer defined _H. pylori_ as a class I carcinogen for gastric cancer, and it may act as a “promoter” to trigger the following cascade lesions: normal gastric mucosa → chronic non-atrophic gastritis → atrophic gastritis → intestinal epithelial metaplasia → dysplasia → gastric cancer. According to the data from WHO in 2012, approximately 15.4% of cancers worldwide were attributed to infection. Among these infections, _H. pylori_ infection, which causes gastric cancer, ranks first (35.4%). In China, approximately 24.2% of cancers were attributed to infection, and _H. pylori_ infection-related cancer accounted for 45%. In 2015, the Kyoto global consensus report directly defined _H. pylori_-positive gastritis as an infectious disease and included it in the “International Classification of Diseases”. At the same time, it passed a new consensus that once _H. pylori_ infection is detected, patients need to accept eradication therapy.

_H. pylori_ infection plays a critical role in the process of carcinogenesis through a series of complex regulations. It can promote the proliferation of epithelial cells and directly activate signaling pathways related to early proliferation, leading to increased DNA synthesis and a higher risk of malignant tumors. In our previous study, we found that _H. pylori_ could accelerate PTEN phosphorylation, which activated the PI3K/Akt signaling and promoted cell survival. Furthermore, PLK1 was reported to induce PTEN phosphorylation, activating the PI3K/Akt pathway, which increases tumor susceptibility. Therefore, in this study, we aimed to determine the role of PLK1 in _H. pylori_ infection-induced gastric carcinogenesis. In addition, the effect of _H. pylori_ infection on PLK1/p-PTEN/PI3K/Akt signaling was assessed to identify its underlying mechanisms.

### Materials and methods

#### Patients and tissue specimens

A total of 166 gastric tissue samples were collected from patients who underwent a gastroduodenoscopy at The First Affiliated Hospital of Nanchang University from January 2010 to February 2017, which included 38 cases of chronic non-atrophic gastritis (18 _H. pylori_ positive, 20 _H. pylori_ negative), 43 cases of intestinal metaplasia (21 _H. pylori_ positive, 22 _H. pylori_ negative), 40 cases of dysplasia (20 _H. pylori_ positive, 20 _H. pylori_ negative), and 45 cases of gastric cancer (23 _H. pylori_ positive, 22 _H. pylori_ negative). The clinical characteristics of these patients are summarized in Table 1, and there was no significant difference in the age and gender distribution among these groups. Pathologic diagnosis and classification were carried out as previously described, and all patients were examined for _H. pylori_ infection using Giemsa staining and a rapid urease test. This study was approved by the Medical Research Ethics Committee and the Institutional Review Board of the First Affiliated Hospital of Nanchang University. Written informed consent was obtained from the study subjects.

#### Mongolian gerbils

Five- to eight-week-old specific-pathogen-free male Mongolian gerbils (30–50 g) were provided by Zhejiang Academy of Medical Sciences (Hangzhou, Zhejiang, China). As previously described, they were maintained in an isolated clean room with a regulated temperature (20°C–22°C), humidity (approximately 55%), and 12/12-h light/dark cycle, with ad libitum rodent diet and water, and then infected with _H. pylori_ after 1 week of observation. Animals were euthanized at 6 months, 12 months, and 18 months post-infection, and linear strips of gastric tissue extending from the squamocolumnar junction through the proximal duodenum were collected. All protocols for animal experiments using gerbils were approved by the

### Table 1 Clinical characteristics of patients with different stages of gastric carcinogenesis

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Gender</th>
<th>Age, years (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNAG</td>
<td>38</td>
<td>19</td>
<td>50.16±11.02</td>
</tr>
<tr>
<td>IM</td>
<td>43</td>
<td>21</td>
<td>54.26±9.06</td>
</tr>
<tr>
<td>Dys</td>
<td>40</td>
<td>21</td>
<td>53.63±10.55</td>
</tr>
<tr>
<td>GC</td>
<td>45</td>
<td>23</td>
<td>56.80±12.14</td>
</tr>
<tr>
<td>Total</td>
<td>166</td>
<td>84</td>
<td>53.86±11.01</td>
</tr>
</tbody>
</table>

**Abbreviations:** CNAG, chronic non-atrophic gastritis; IM, intestinal metaplasia; Dys, dysplasia; GC, gastric cancer.
Ethics Committee of the First Affiliated Hospital of Nan-chang University (No: 018).

**H. pylori strain and cell lines**
The CagA+ and VagA+ *H. pylori* type strain ATCC43504 was obtained from the National Institute for Communicable Diseases and Prevention of Chinese Centers for Disease Control and Prevention (Beijing, China). *H. pylori* was cultured on Campylobacter agar plates at 37°C under microaerophilic conditions for 24 h and then subcultured in Brucella broth (Shanghai Municipal Center for Disease Control and Prevention) containing 10% fetal bovine serum (FBS; Thermo Fisher Scientific Inc., Waltham, MA, USA) at 37°C under a microaerophilic atmosphere for 16–18 h.19 Gastric cancer MKN-28 cells were obtained from the Beijing Institute for Cancer Research (Beijing, China). MKN-28 was cultured in RPMI-1640 supplemented with 10% FBS, 100 U penicillin, and 100 μg/mL streptomycin (Thermo Fisher Scientific Inc.) at 37°C in an atmosphere of 5% CO₂.

**Reagents**
Inhibition of PLK1 was achieved with BI2536 (200 nM; Selleck Chemicals, Houston, TX, USA) and a CCK-8 kit (BB-4202-2; BestBio, Shanghai, China) was used.

**Immunoblotting**
Western blotting was performed according to standard methods as described previously21 using anti-PTEN (#9559; Cell Signaling Technology, Danvers, MA, USA; 1:1,000), anti-phosphorylated (p)-PTEN (Ser380/Thr382/383) (#9554; Cell Signaling Technology; 1:1,000), anti-P13K (#4249; Cell Signaling Technology; 1:1,000), anti-Akt (#4691; Cell Signaling Technology; 1:1,000), anti-phosphorylated (p)-Akt (Ser473) (#9271; Cell Signaling Technology; 1:1,000), anti-Cyclin D1 (#2978; Cell Signaling Technology; 1:1,000), anti-Bad (#9239; Cell Signaling Technology; 1:1,000), anti-phosphorylated (p)-Bad (Ser136) (#4366; Cell Signaling Technology; 1:1,000), anti-GAPDH (#2118; Cell Signaling Technology; 1:1,000), and anti-PLK1 antibodies (ab17056; 1:1,000; Abcam, Cambridge, UK).

**Immunohistochemistry**
Immunohistochemistry was performed on paraffin sections of human biopsy specimens or Mongolian gerbil gastric tissues using an anti-PLK1 antibody (ab17056; 1:400 [biopsy], [human gastric tissues]; 1:200 [biopsy], [Mongolian gerbil gastric tissues]; Abcam) following previously described methods.21 The negative control sections were incubated with PBS without the primary antibodies. The stained sections were chosen, reviewed, and scored from five randomly selected high-power fields (40× objective lens) by two pathologists blinded to the histopathologic data. Grading discrepancies were re-reviewed and discussed to obtain a final score. Epithelial cells with yellow or brown staining in the nucleus and/or cytoplasm were defined as positive for immunoreactivity. The percentage of immunoreactive cells from 100 cells in each field was averaged from the five fields and scored as follows: 0 <5.0% immunoreactive; 1 = 5.1%–25.0%; 2 = 25.1%–50.0%; 3 = 50.1%–75.0%; and 4 >75.0%. Moreover, the staining intensity was also semi quantitatively assessed as follows: 0 = no staining; 1 = weak staining; 2 = moderate staining; and 3 = strong staining. The overall protein expression level was then reported as a grade calculated from an integral score of the “area × intensity” as follows: grade 1 = score 0–2 (negative); grade 2 = score 3–5 (weakly positive); grade 3 = score 6–8 (moderately positive); and grade 4 = score 9–12 (strongly positive).

**Statistical analysis**
Data are expressed as a percentage of the control or the mean ± SD. Differences in categorical variables were examined using chi-square tests. Differences in numerical variables, such as patient age, were analyzed using ANOVA among the groups. The differences in numerical variables between differently defined groups were evaluated using Kruskal–Wallis tests or Mann–Whitney tests. p <0.05 was considered statistically significant.

**Results**
**PLK1 is upregulated in gastric cancer tissues**
Western blot was performed to assess PLK1 expression in protein samples from gastric cancer tissues and the paired adjacent mucosa of patients. An increase in PLK1 expression was detected in gastric cancer tissues compared to the paired adjacent mucosa (23/26, 88.46%) (Figure 1).

**Expression of PLK1 in different stages of gastric carcinogenesis in relation to *H. pylori* infection**
Immunohistochemistry was performed to evaluate the expression of PLK1 in patients with different stages of gastric carcinogenesis. PLK1 was increased in intestinal metaplasia, dysplasia, and gastric cancer tissues compared to chronic non-atrophic gastritis tissues (p <0.01), and PLK1 was significantly lower in intestinal metaplasia than dysplasia and...
gastric cancer ($p<0.05$, $p<0.01$) (Figure 2A and C). These data suggest that PLK1 may contribute to gastric carcinogenesis at the early stage.

As it has been postulated that *H. pylori* infection may trigger gastric carcinogenesis, the same cohort of patients were divided into *H. pylori*-positive and -negative groups, and the expression of PLK1 was compared between these two groups. Immunohistochemical analysis revealed that there was a significant difference among these four groups in *H. pylori*-positive patients. PLK1 expression was decreased

Figure 1 PLK1 is upregulated in gastric cancer tissues. Expression level of PLK1 was measured in gastric tumor samples (T) and their non-cancerous counterparts (N). GAPDH was used as an internal control. Densitometric units of T are expressed as a fold of its corresponding N. ***$p<0.001$.

Abbreviation: PLK1, polo-like kinase 1.

Figure 2 Expression of PLK1 in different stages of gastric carcinogenesis in relation to *Helicobacter pylori*. Gastric tissue samples were stained with antibodies against PLK1; (A) immunoreactive cells positive for PLK1 were semi-quantitatively assessed and the protein expression levels are expressed as grade 1–4; (B) all patients in various stages of gastric lesions; (C, D) patients with various stages of gastric lesions with or without *H. pylori* infection. Mean grades (–) for protein expression are shown. *$p<0.05$; ***$p<0.01$; ***$p<0.001$.

Abbreviations: PLK1, polo-like kinase 1; CNAG, chronic non-atrophic gastritis; IM, intestinal metaplasia; Dys, dysplasia; GC, gastric cancer.
in chronic non-atrophic gastritis compared to intestinal metaplasia, dysplasia, and gastric cancer tissues from *H. pylori*-positive tissues \( (p<0.05) \) (Figure 2D). Furthermore, in intestinal metaplasia tissues, PLK1 was much higher in *H. pylori*-positive patients than in *H. pylori*-negative patients \( (p<0.001) \) (Figure 2B and D). These results suggest that PLK1 is related to *H. pylori* infection in the process of gastric carcinogenesis.

**H. pylori** infection induces high expression of PLK1 in gastric tissue from Mongolian gerbils

To confirm that PLK1 is related to *H. pylori* infection in the process of gastric carcinogenesis in vivo, we performed immunohistochemical analysis of PLK1 in gastric tissue samples of Mongolian gerbils with or without *H. pylori* infection. Our results showed that expression of PLK1 was greatly enhanced in the *H. pylori*-positive group compared to the *H. pylori*-negative group at all time points, such as at the 6th month, the 12th month, and the 18th month post-bacterial inoculation \( (p<0.05, p<0.01, p<0.001) \). In addition, the significance was more obvious with longer *H. pylori* infection (Figure 3).

**PLK1 is involved in *H. pylori*-promoted cancer cell proliferation**

Cell proliferation assessment using a CCK8 assay showed that *H. pylori* could increase MKN-28 cell viability in both dose- and time-dependent manner \( (p<0.05) \) (Figure 4A). To determine the role of PLK1 in *H. pylori*-promoted cancer cell proliferation, we performed cell proliferation assessments using a CCK8 assay. Our results showed that PLK1 expression was significantly higher in the *H. pylori*-positive group compared to the *H. pylori*-negative group at all time points, such as at the 6th month, the 12th month, and the 18th month post-bacterial inoculation \( (p<0.05, p<0.01, p<0.001) \). In addition, the significance was more obvious with longer *H. pylori* infection (Figure 3).

**Figure 3** *Helicobacter pylori* infection induces high expression of PLK1 in gastric tissue from Mongolian gerbils. (A) Gastric tissue sections from *H. pylori*-infected gerbils were stained with antibodies against PLK1. (B) Immunoreactive cells were semi quantitatively assessed and the protein expression levels are expressed as grade 1–4. Mean grades \( (\ldots) \) for protein expression are shown. \( *p<0.05; **p<0.01; ***p<0.001. \)

**Abbreviation:** PLK1, polo-like kinase 1.
cell proliferation, MKN-28 cells were pretreated with the pharmacological PLK1 inhibitor BI 2536. As expected, the growth rate of MKN-28 cells significantly decreased even with H. pylori (multiplicity of infection [MOI] = 200) infection after pretreatment with BI 2536, and the viability of cells pretreated with dimethyl sulfoxide (DMSO) had a similar trend to that observed in untreated cells (p < 0.05) (Figure 4B), suggesting that H. pylori infection also induces cell survival in vitro and that PLK1 is involved in the regulation.

H. pylori infection induces PLK1-mediated activation of the PI3K/Akt pathway

Incubation of MKN-28 cells with different doses of H. pylori (MOI = 10, 50, 100, 200) resulted in a dose-dependent increase of PLK1 (Figure 5A). At the same time, we observed gradually enhanced expression of p-PTEN, p-Akt, cyclin D1, and p-Bad with the increased dose of H. pylori infection (p < 0.05) (Figure 5B).

To further confirm the effect of H. pylori infection on activation of the PLK1 and Akt pathway, we incubated MKN-28 cells with H. pylori (MOI = 200) at different time points. We found that the expression levels of PLK1 and cyclin D1 and the ratios of p-PTEN/PTEN, p-Akt/Akt, and p-Bad/Bad were increased in a time-dependent manner (p < 0.05); however, there were no significant differences in the control (Figure 6A and B).

To certify whether H. pylori-induced activation of Akt pathway is dependent on PLK1, we used the PLK1 inhibitor BI 2536 to pretreat MKN-28 cells prior to H. pylori infection. We found that after H. pylori infection, expression levels of PLK1, p-PTEN, p-Akt, cyclin D1, and p-Bad were significantly decreased in the BI-2536-treated group compared to the DMSO and the untreated group (p < 0.05) (Figure 7), suggesting that PLK1 is involved in H. pylori infection-induced activation of the Akt pathway.

Discussion

Development of gastric cancer is a multistaged and orderly process, which proceeds from normal mucosa to chronic non-atrophic gastritis, intestinal metaplasia, dysplasia, and finally gastric cancer. H. pylori infection often plays the initial and leading role in this process. We previously reported that increased PTEN phosphorylation at residues Ser380/Thr382/383 contributed to H. pylori infection-induced gastric carcinogenesis. PLK1 could promote PTEN phosphorylation at these residues. Therefore, the present study focused on the unknown role of PLK1 in H. pylori-regulated cancer occurrence and development.

Normally, PLK1 is expressed highly in tissues with an actively proliferating cell population, and PLK1 is expressed poorly in gastric tissues. Jang et al detected the expression of PLK1 in 280 patients with gastric cancer and found that 95% of cancer patients had high expression of PLK1, while there was almost no expression of PLK1 in its paired adjacent mucosa, which is consistent with our findings. A sustained increase of PLK1 in intestinal metaplasia, dysplasia, and gastric cancer tissues could be detected in our study. Additionally, the data showed that PLK1 was significantly lower in patients with chronic non-atrophic gastritis who were infected with H. pylori, but there was no significant difference among patients at later stages, suggesting that PLK1 related to H. pylori may contribute to gastric carcinogenesis at the early stage. To confirm the human sample results, we established H. pylori-infected Mongolian gerbil models to further demonstrate the role of PLK1 in H. pylori-induced...
cancer occurrence. We found that PLK1 expression was positively related with the duration of *H. pylori* infection, which supported our human sample results.

According to numerous studies and our preliminary experiments, PTEN can negatively regulate the PI3K/Akt pathway, and the latter is important in promoting proliferation, controlling cell survival, and inhibiting apoptosis.24-27 Our present study revealed that *H. pylori* infection could increase expression of PLK1, thus inducing PTEN phosphorylation and then the activation of the PI3K/Akt pathway. Meanwhile,
expression of p-PTEN, p-Akt, cyclin D1, and p-Bad began to increase 30 min after *H. pylori* infection and continued throughout the duration of the infection. The control group, which was not exposed to infection, exhibited no significant changes in the expression of p-PTEN, p-Akt, cyclin D1, and p-Bad. This suggests that *H. pylori* may activate the PTEN/Akt signaling pathway at the early stage of infection *in vitro*. Furthermore, a broad range of studies confirmed that *H. pylori* infection could activate the Akt signaling pathway at the early stage. 19,28,29 We, therefore, hypothesized that at the early stage

---

**Figure 6** *Helicobacter pylori* infection induces PlK1-mediated activation of the PI3K/Akt pathway in a time-dependent manner. Cultures of MKN-28 cells were incubated at different time points with *H. pylori* infection (MOI = 200). Immunoblotting was used to quantify the expression levels of PlK1 (A) and Akt pathway-related proteins (B). The data are representative of three independent experiments. The samples were derived from the same experiment and the blots were processed in parallel. **p < 0.01; ***p < 0.001.

**Abbreviations:** MOI, multiplicity of infection; PlK1, polo-like kinase 1.
of infection, *H. pylori* can increase PLK1 by activation of the Akt signaling pathway. We believe this process underlies the disordered proliferation of gastric mucosal cells, which ultimately contributes to gastric carcinogenesis and increased risk of tumor proliferation.

Is PLK1 really involved in *H. pylori*-promoted cancer cell proliferation? To answer this question, we added the PLK1 inhibitor BI 2536. We pretreated MKN-28 cells with BI 2536 and DMSO and then co-cultured them with *H. pylori* at an MOI of 200:1. The growth rate of MKN-28 cells significantly decreased in the BI 2536-pretreated group, suggesting that *H. pylori* infection induces cell survival in vitro and that PLK1 is involved in the regulation. Additionally, we observed that the expression levels of p-PTEN, p-Akt, cyclin D1, and p-Bad in the BI 2536-pretreated group were significantly downregulated. Inhibition of PLK1 blocked the activation of the PTEN/Akt pathway, demonstrating that activation of the Akt pathway by *H. pylori* is dependent on PLK1.

Although our results contribute to a deeper understanding of *H. pylori* infection-related gastric carcinogenesis, there are some limitations in the present study. The study focused only on a CagA+ and VagA+ strain of *H. pylori*, actually in addition to CagA+ and VagA+, *H. pylori* also secretes many other virulence factors, including iceA, oipA, urease, babA2, Lewis b, hrgA, dupA, picA, picB, and so on. These virulence factors encode genetic polymorphism of their proteins which can cause different pathogenicity of *H. pylori* and then determine the clinical outcome of *H. pylori* infection-related diseases. However, the virulence factors responsible for PLK1/Akt interactions and related cancer prognosis are still not clear.

**Conclusion**

We confirmed the role of PLK1/p-PTEN/P13K/Akt in *H. pylori*-induced carcinogenesis (detail in Figure 8). The elucidation of this mechanism may aid the development of new control strategies for *H. pylori* infection-related disease.
**References**


**Acknowledgments**

This work was supported in part by grants from the National Natural Science Foundation of China (81460377, 81270479, 81470832, and 81670507), the Natural Science Foundation of Jiangxi Province, China (20151BAB205041), the Graduate Student Innovation Foundation of Jiangxi Province, China (YC2015-B021), the Jiangxi Province Talent 555 Project, and the National Science and Technology Major Projects program for “Major New Drugs Innovation and Development” of China (2011ZX09302-007-03). We thank Prof JZ Zhang at the National Institute for Communicable Diseases and Prevention of Chinese Centers for Disease Control and Prevention for providing the *H. pylori* type strain ATCC43504.

**Disclosure**

The authors report no conflicts of interest in this work.


